Publication
Envelope C2-V3-C3-specific antibodies from HIV-1 infected patients from Angola correlate with neutralization activity in plasma
dc.contributor.author | Calado, R. | |
dc.contributor.author | Duarte, J. | |
dc.contributor.author | Diniz, A. R. | |
dc.contributor.author | Borrego, P. | |
dc.contributor.author | Marcelino, J. M. | |
dc.contributor.author | Wilton, J. | |
dc.contributor.author | Bartólo, I. | |
dc.contributor.author | Clemente, S. | |
dc.contributor.author | Taveira, N. | |
dc.date.accessioned | 2016-10-12T14:19:40Z | |
dc.date.available | 2016-10-12T14:19:40Z | |
dc.date.issued | 2015-03-22 | |
dc.description | Poster presented at the 2015 Keystone Symposia Conference X5: HIV Vaccines. Banff, Alberta, Canada, 22-27 March 2015 | pt_PT |
dc.description.abstract | "Development of immunogens that induce broadly neutralizing antibodies (bNAbs) is a major goal in HIV-1 vaccine field. Recently, we found that bNAbs can be elicited in Balb/c mice against HIV-2 by using a prime-boost vaccination strategy combining recombinant Vaccinia virus expressing a truncated form of the SU glycoprotein and a polypeptide comprising the C2, V3 and C3 envelope regions. We want to test the hypothesis that a similar vaccination strategy can also be effective for HIV-1. We also want to test the hypothesis that envelope glycoproteins derived from ancestral HIV-1 isolates from Angola may induce a broader neutralizing antibody response compared to envelope glycoproteins derived from contemporaneous isolates." | pt_PT |
dc.identifier.uri | http://hdl.handle.net/10400.26/15089 | |
dc.language.iso | eng | pt_PT |
dc.relation | Molecular epidemiology, drug resistance and pathogenesis of HIV and TB in Angola: the Angolan PErinatal HIV Cohort (APEHC) | |
dc.subject | Antibodies | pt_PT |
dc.subject | HIV-1 infected patients | pt_PT |
dc.subject | Angola | pt_PT |
dc.subject | Plasma | pt_PT |
dc.subject | Neutralization activity | pt_PT |
dc.title | Envelope C2-V3-C3-specific antibodies from HIV-1 infected patients from Angola correlate with neutralization activity in plasma | pt_PT |
dc.type | conference object | |
dspace.entity.type | Publication | |
oaire.awardTitle | Molecular epidemiology, drug resistance and pathogenesis of HIV and TB in Angola: the Angolan PErinatal HIV Cohort (APEHC) | |
oaire.awardURI | info:eu-repo/grantAgreement/FCT/3599-PPCDT/PTDC%2FSAU-EPI%2F122400%2F2010/PT | |
oaire.awardURI | info:eu-repo/grantAgreement/FCT/3599-PPCDT/VIH%2FSAU%2F0029%2F2011/PT | |
oaire.awardURI | info:eu-repo/grantAgreement/FCT/3599-PPCDT/PTDC%2FSAU-FAR%2F115290%2F2009/PT | |
oaire.citation.conferencePlace | Banff, Alberta, Canada | pt_PT |
oaire.citation.title | 2015 Keystone Symposia Conference X5: HIV Vaccines | pt_PT |
oaire.fundingStream | 3599-PPCDT | |
oaire.fundingStream | 3599-PPCDT | |
oaire.fundingStream | 3599-PPCDT | |
project.funder.identifier | http://doi.org/10.13039/501100001871 | |
project.funder.identifier | http://doi.org/10.13039/501100001871 | |
project.funder.identifier | http://doi.org/10.13039/501100001871 | |
project.funder.name | Fundação para a Ciência e a Tecnologia | |
project.funder.name | Fundação para a Ciência e a Tecnologia | |
project.funder.name | Fundação para a Ciência e a Tecnologia | |
rcaap.rights | openAccess | pt_PT |
rcaap.type | conferenceObject | pt_PT |
relation.isProjectOfPublication | c3b60260-41c1-4212-93cd-191d5b2e6133 | |
relation.isProjectOfPublication | e63cde82-fa32-4aed-90e7-c9443427f2e1 | |
relation.isProjectOfPublication | 15aded3d-70a1-4e02-8508-f5e6a4e56f9a | |
relation.isProjectOfPublication.latestForDiscovery | c3b60260-41c1-4212-93cd-191d5b2e6133 |